Tenax Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tenax Therapeutics, Inc. (Nasdaq: TENX) is a Phase 3 development-stage pharmaceutical company focused on developing novel therapies for cardiopulmonary diseases, particularly pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The company develops TNX-103, an oral formulation of levosimendan that has completed Phase 2 trials for PH-HFpEF; TNX-201, an oral enteric-coated imatinib for pulmonary arterial hypertension (PAH); and earlier-stage candidates including TNX-101 and TNX-102 for related pulmonary hypertension indications. Founded in 1967 and headquartered in Chapel Hill, North Carolina, Tenax Therapeutics operates primarily in the United States with a small team of experts guiding its clinical programs targeting unmet needs in cardiovascular and pulmonary care. In August 2024, the company closed an oversubscribed $100 million private placement led by BVF Partners LP with participation from Venrock Healthcare Capital Partners, Vivo Capital, Janus Henderson Investors and others to fund the ongoing LEVEL Phase 3 trial of TNX-103 and initiate a second Phase 3 study in 2025, accelerating its path to NDA submission; this followed a $25 million private placement with RTW Investments in March 2025 to support clinical trials and operations.
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200-Day Moving Average – What’s Next?
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Head-To-Head Contrast: Gyre Therapeutics (NASDAQ:GYRE) versus Tenax Therapeutics (NASDAQ:TENX)
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
Tenax Therapeutics: A Speculative Buy
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving Average – What’s Next?
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Tenax Therapeutics to Participate in Upcoming Investor Conferences
Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript